Rakuten Aspyrian Stock

Tumor-targeted precision therapies

Sign up today and learn more about Rakuten Aspyrian Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors



San Diego CA, US

Total Funding


About Rakuten Aspyrian Stock

Rakuten Aspyrian is a privately funded clinical stage biotechnology company developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy. Photoimmunotherapy combines key advantages of antibody-mediated targeting of the cancer cells to achieve high tumor specificity, together with laser-activation of a biophysical mechanism that induces rapid cancer cell death with precision. Treatments with the Photoimmunotherapy platform lead to targeted and rapid tumor cell death by necrosis, with minimal effects on normal tissue. Rakuten Aspyrian is studying Photoimmunotherapy for use as a monotherapy and in combination with other drugs. Founded in 2013, the company is based in San Diego, California.


Funding History

January 2015$8.4M
July 2015$4.3M
March 2016$40.0M
July 2017$15.1M
August 2018$150M
December 2018$134M


Chief Executive Officer

Hiroshi Mikitani

COO & President

Takashi Toraishi

Chief Technical Officer

Carlos A. Garcia

Finances and Operations

Agatha Martindale

Head of Chemistry

Lew Makings


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: